# A PHASE II, RANDOMIZED TRIAL TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT VULVAR CANCER

> **NCT07101848** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Hospital Israelita Albert Einstein** · enrollment: 42 (estimated)

## Conditions studied

- Vulvar Cancers

## Interventions

- **DRUG:** Cemiplimab

## Key facts

- **NCT ID:** NCT07101848
- **Lead sponsor:** Hospital Israelita Albert Einstein
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11-01
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07101848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07101848, "A PHASE II, RANDOMIZED TRIAL TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT VULVAR CANCER". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07101848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*